DE60328087D1 - Aryl substituierte pyrimidine und deren verwendung - Google Patents
Aryl substituierte pyrimidine und deren verwendungInfo
- Publication number
- DE60328087D1 DE60328087D1 DE60328087T DE60328087T DE60328087D1 DE 60328087 D1 DE60328087 D1 DE 60328087D1 DE 60328087 T DE60328087 T DE 60328087T DE 60328087 T DE60328087 T DE 60328087T DE 60328087 D1 DE60328087 D1 DE 60328087D1
- Authority
- DE
- Germany
- Prior art keywords
- aryl substituted
- substituted pyrimidine
- pyrimidine
- aryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36354402P | 2002-03-13 | 2002-03-13 | |
PCT/IB2003/001837 WO2003076414A2 (en) | 2002-03-13 | 2003-03-13 | Aryl substituted pyrimidines and the use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60328087D1 true DE60328087D1 (de) | 2009-08-06 |
Family
ID=27805282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60328087T Expired - Lifetime DE60328087D1 (de) | 2002-03-13 | 2003-03-13 | Aryl substituierte pyrimidine und deren verwendung |
Country Status (27)
Country | Link |
---|---|
US (1) | US7229993B2 (de) |
EP (1) | EP1483247B1 (de) |
JP (1) | JP4473583B2 (de) |
KR (1) | KR20040099324A (de) |
CN (1) | CN1646500A (de) |
AP (1) | AP2004003152A0 (de) |
AT (1) | ATE434610T1 (de) |
AU (1) | AU2003223049A1 (de) |
BR (1) | BR0308451A (de) |
CA (1) | CA2479036A1 (de) |
CO (1) | CO5611139A2 (de) |
CR (1) | CR7526A (de) |
CY (1) | CY1109355T1 (de) |
DE (1) | DE60328087D1 (de) |
DK (1) | DK1483247T3 (de) |
EA (1) | EA200401120A1 (de) |
EC (1) | ECSP045360A (de) |
ES (1) | ES2328471T3 (de) |
IL (1) | IL163940A0 (de) |
IS (1) | IS7468A (de) |
MA (1) | MA27196A1 (de) |
MX (1) | MXPA04008901A (de) |
NO (1) | NO20044311L (de) |
PT (1) | PT1483247E (de) |
SI (1) | SI1483247T1 (de) |
TN (1) | TNSN04174A1 (de) |
WO (1) | WO2003076414A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169782B2 (en) * | 2001-07-16 | 2007-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
EA200500289A1 (ru) * | 2002-07-31 | 2005-06-30 | Еуро-Селтик С. А. | Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов |
US20040152696A1 (en) * | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
JP2007505121A (ja) * | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
EP1732541A4 (de) * | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | Cyclische verbindungen |
CA2600067A1 (en) * | 2005-03-04 | 2006-09-14 | Alsgen, Inc. | Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues 6 |
US20070135437A1 (en) * | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
CA2622472C (en) | 2005-09-14 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
EP2593434A1 (de) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridinverbindungen als kaliumkanalblocker |
KR20130056345A (ko) | 2010-09-17 | 2013-05-29 | 퍼듀 퍼머 엘피 | 피리딘 화합물 및 그의 용도 |
CA2813704A1 (en) | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
EP2655330B1 (de) | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substutuierte pyridine als kaliumkanalblocker |
EP2753606B1 (de) | 2011-09-02 | 2017-07-05 | Purdue Pharma LP | Pyrimidine als natriumkanalblocker |
WO2013064883A1 (en) | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
US9388137B2 (en) | 2011-10-31 | 2016-07-12 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
WO2013136170A1 (en) | 2012-03-16 | 2013-09-19 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
CA2941171C (en) | 2013-03-04 | 2020-07-07 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
JP6186494B2 (ja) | 2013-03-15 | 2017-08-23 | パーデュー、ファーマ、リミテッド、パートナーシップ | カルボキサミド誘導体及びその使用 |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9884865B2 (en) | 2013-08-26 | 2018-02-06 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
US9745287B2 (en) | 2013-12-20 | 2017-08-29 | Purdue Pharma L.P. | Pyrimidines and use thereof |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
WO2015099841A1 (en) | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles and use thereof |
US9902726B2 (en) | 2013-12-30 | 2018-02-27 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
JP6526023B2 (ja) | 2014-01-24 | 2019-06-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ピリジン類及びピリミジン類並びにその使用 |
CA2939501C (en) | 2014-02-12 | 2020-07-07 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
MA39956A (fr) | 2014-05-06 | 2015-11-12 | Purdue Pharma Lp | Analogues du benzomorphane et leur utilisation |
WO2015192039A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Heterocyclic morphinan derivatives and use thereof |
CA2951697A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
JP6762308B2 (ja) | 2015-02-19 | 2020-09-30 | パーデュー、ファーマ、リミテッド、パートナーシップ | 胃排出の減少方法及び組成物 |
WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1122533B (de) | 1959-04-18 | 1962-01-25 | Knoll Ag Chemischer Fabriken | Verfahren zur Herstellung basisch substituierter 4-Amino-6-hydroxypyrimidine |
MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
US4492792A (en) | 1982-02-04 | 1985-01-08 | Ube Industries, Ltd. | Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives |
GB8909560D0 (en) * | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Chemical compounds |
KR930702312A (ko) * | 1990-08-31 | 1993-09-08 | 아만 히데아키 | 피리미딘 유도체 및 의약 |
DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPH0558997A (ja) | 1991-09-04 | 1993-03-09 | Mitsubishi Kasei Corp | チオカルバモイルアセトニトリル誘導体 |
US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
KR950703539A (ko) | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
BR9307264A (pt) | 1992-10-16 | 1999-05-11 | Nippon Soda Co | Derivados de pirimidina herbicida e fungicida |
DE4493151T1 (de) | 1993-05-13 | 1995-07-20 | Nippon Kokan Kk | Pyrimidinderivate und Arzneimittel |
GB2281295A (en) * | 1993-08-26 | 1995-03-01 | Zeneca Ltd | (2-Fluoroethyl) thio-substituted pyrimidines as nematicides |
US5569655A (en) | 1993-09-14 | 1996-10-29 | Sterling Winthrop Inc. | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof |
US5602156A (en) | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
WO1995011235A1 (en) | 1993-10-20 | 1995-04-27 | The Upjohn Company | Pyrimidinones as antiarthritic and anti-inflammatories |
US5795905A (en) * | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US5874440A (en) | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
GB9525296D0 (en) | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
AR020590A1 (es) | 1998-06-02 | 2002-05-22 | Cadus Pharmaceutical Corp | 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden |
IL145508A0 (en) | 1999-03-26 | 2002-06-30 | Euro Celtique Sa | Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same |
CO5210940A1 (es) | 1999-05-04 | 2002-10-30 | Novartis Ag | Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen |
EP1204645A2 (de) | 1999-08-04 | 2002-05-15 | Millennium Pharmaceuticals, Inc. | An den melanocortin-4-rezeptor bindende verbindungen und verfahren ihrer verwendung |
DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
JP2003519102A (ja) | 1999-12-02 | 2003-06-17 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アデノシンa▲下1▼、a▲下2a▼およびa▲下3▼受容体に対して特異的な化合物並びにその使用 |
AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
CN1321112C (zh) | 2000-03-24 | 2007-06-13 | 欧洲凯尔特股份有限公司 | 作为钠通道阻滞剂的芳基取代的吡唑、三唑和四唑化合物 |
US6335354B2 (en) | 2000-03-31 | 2002-01-01 | Cocensys Inc. | Aminopyridines and methods of using thereof |
US7169782B2 (en) | 2001-07-16 | 2007-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
-
2003
- 2003-03-13 BR BR0308451-5A patent/BR0308451A/pt not_active Application Discontinuation
- 2003-03-13 JP JP2003574634A patent/JP4473583B2/ja not_active Expired - Fee Related
- 2003-03-13 KR KR10-2004-7014305A patent/KR20040099324A/ko not_active Application Discontinuation
- 2003-03-13 AT AT03719019T patent/ATE434610T1/de active
- 2003-03-13 AP APAP/P/2004/003152A patent/AP2004003152A0/en unknown
- 2003-03-13 EA EA200401120A patent/EA200401120A1/ru unknown
- 2003-03-13 US US10/386,483 patent/US7229993B2/en not_active Expired - Lifetime
- 2003-03-13 MX MXPA04008901A patent/MXPA04008901A/es unknown
- 2003-03-13 WO PCT/IB2003/001837 patent/WO2003076414A2/en active Application Filing
- 2003-03-13 CN CNA038083833A patent/CN1646500A/zh active Pending
- 2003-03-13 EP EP03719019A patent/EP1483247B1/de not_active Expired - Lifetime
- 2003-03-13 ES ES03719019T patent/ES2328471T3/es not_active Expired - Lifetime
- 2003-03-13 PT PT03719019T patent/PT1483247E/pt unknown
- 2003-03-13 SI SI200331664T patent/SI1483247T1/sl unknown
- 2003-03-13 DE DE60328087T patent/DE60328087D1/de not_active Expired - Lifetime
- 2003-03-13 AU AU2003223049A patent/AU2003223049A1/en not_active Abandoned
- 2003-03-13 DK DK03719019T patent/DK1483247T3/da active
- 2003-03-13 IL IL16394003A patent/IL163940A0/xx unknown
- 2003-03-13 CA CA002479036A patent/CA2479036A1/en not_active Abandoned
-
2004
- 2004-09-10 TN TNP2004000174A patent/TNSN04174A1/en unknown
- 2004-09-24 IS IS7468A patent/IS7468A/is unknown
- 2004-10-11 MA MA27905A patent/MA27196A1/fr unknown
- 2004-10-12 EC EC2004005360A patent/ECSP045360A/es unknown
- 2004-10-12 CO CO04101907A patent/CO5611139A2/es not_active Application Discontinuation
- 2004-10-12 NO NO20044311A patent/NO20044311L/no unknown
- 2004-10-13 CR CR7526A patent/CR7526A/es not_active Application Discontinuation
-
2009
- 2009-09-10 CY CY20091100941T patent/CY1109355T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CR7526A (es) | 2008-08-12 |
SI1483247T1 (sl) | 2009-12-31 |
EP1483247B1 (de) | 2009-06-24 |
JP4473583B2 (ja) | 2010-06-02 |
PT1483247E (pt) | 2009-08-18 |
KR20040099324A (ko) | 2004-11-26 |
AU2003223049A1 (en) | 2003-09-22 |
TNSN04174A1 (en) | 2007-03-12 |
BR0308451A (pt) | 2005-01-11 |
CA2479036A1 (en) | 2003-09-18 |
IS7468A (is) | 2004-09-24 |
CO5611139A2 (es) | 2006-02-28 |
ECSP045360A (es) | 2005-01-03 |
CN1646500A (zh) | 2005-07-27 |
EP1483247A2 (de) | 2004-12-08 |
US7229993B2 (en) | 2007-06-12 |
DK1483247T3 (da) | 2009-08-17 |
ATE434610T1 (de) | 2009-07-15 |
JP2005526069A (ja) | 2005-09-02 |
NO20044311L (no) | 2004-12-10 |
US20030236273A1 (en) | 2003-12-25 |
CY1109355T1 (el) | 2014-07-02 |
AP2004003152A0 (en) | 2004-12-31 |
IL163940A0 (en) | 2005-12-18 |
WO2003076414A2 (en) | 2003-09-18 |
WO2003076414A3 (en) | 2003-12-24 |
MA27196A1 (fr) | 2005-01-03 |
MXPA04008901A (es) | 2004-11-26 |
ES2328471T3 (es) | 2009-11-13 |
EA200401120A1 (ru) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60328087D1 (de) | Aryl substituierte pyrimidine und deren verwendung | |
ATE489369T1 (de) | Pyrimidinderivate und deren verwendung als cb2- modulatoren | |
DK1487805T3 (da) | Pyrimidinderivater | |
DE60333166D1 (de) | Pyridin- und pyrimidin-derivate | |
ATE346056T1 (de) | Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren | |
DE60325761D1 (de) | Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren | |
ATE420659T1 (de) | Criptoblockierende antikörper und deren verwendung | |
DE602004021904D1 (de) | Gyraseinhibitoren und deren verwendungen | |
DK1474420T3 (da) | Quinazolinforbindelser | |
DK1847539T3 (da) | Quinazolin-derivater | |
ATE428710T1 (de) | Substituierte phenylaminothiazole und ihre verwendung | |
DE602004029844D1 (de) | Pigmentdispersion und deren Verwendung | |
ATE418543T1 (de) | Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten | |
DE60330269D1 (de) | Piperazinyl- und diazapanylbenzamide und-benzothioamide | |
ATE551329T1 (de) | Chinazolinonderivate und deren verwendung als cb- agonisten | |
DE60336266D1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten | |
DE10251294B4 (de) | Polyamidformmasse und deren Verwendung | |
DE60318733D1 (de) | Substituierte benzoxazinones und ihre verwendung | |
ATE300525T1 (de) | Uracilverbindungen und deren verwendung | |
ATE400266T1 (de) | N-acylaminoacetonitril-derivate und ihre verwendung zur kontrolle von parasiten | |
DE50300769D1 (de) | Erdalkalialuminosilicatglas und verwendung | |
DE50311406D1 (de) | Verwendung von Formkörpern | |
DE60328713D1 (de) | Blockcopolymer-modifizierte bitumenpappen und deren verwendung | |
ATE428775T1 (de) | R-hydroxynitrillyasen mit verbesserter substratakzeptanz und deren verwendung | |
DE60316134D1 (de) | Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |